MTOR and cancer: Among them, somatic mutations affecting genes involved in PIK3/AKT/MTOR signaling (PIK3CA, AKT1, and MTOR), histone methyltransferase (KMT2D), the cell cycle regulator (CDC27), and WNT/β-catenin pathway (CTNNB1) were the most frequent, suggesting they might confer a selective advantage to cancer metastasis.